Eywa Pharma

What Eywa Pharma does

Eywa Pharma is a global generic pharmaceuticals company founded in April 2015 and headquartered in Singapore, with operating subsidiaries in India (Eywa Pharma Private Ltd, R&D in Chennai at Ticel Bio Park), the United States (Eywa Pharma Inc., commercial operations and historically manufacturing in Cranbury, New Jersey), and the United Kingdom/Europe (Zista Pharma Limited, commercial operations in Stevenage). The company develops and commercializes affordable generic medicines in solid oral dosage forms including tablets, capsules, oral suspensions, and solutions, with a differentiated portfolio strategy spanning niche products with limited or no generic competition, high-volume products, products going off-patent, and formulations addressing historical supply disruptions. The company also pursues strategic private label opportunities, including unit dose products.

The business operates a portfolio-based B2B distribution model, marketing products under the Eywa Label in the US and the Zista brand in the UK/Europe, with distribution through wholesalers, secondary distributors, and buying groups. As of December 2019, the company had filed 38 ANDAs and MAs with over 23 approvals, maintained a 70+ active product portfolio, and employed 100+ people globally. The company applies a Quality by Design framework across its development and manufacturing operations. In 2023, Eywa divested its Cranbury, New Jersey Oral Solid Dosage manufacturing facility to Biocon Generics Inc., which committed over USD 30 million to expand production capacity to 2 billion tablets annually. Post-divestiture, Eywa retains its commercial operations and R&D activities.

Eywa Pharma is backed by Eight Roads Ventures India (the proprietary investment arm of Fidelity International Limited), F-Prime Capital Partners, and Envestor Ventures Limited (part of the Shriram Group), with a USD 30 million funding round in October 2016 supporting formation and growth. Leadership includes co-founders Srinivasan Seshan and R. Jayakumar, both former senior executives at Matrix Laboratories and Mylan with 28-30 years of generics industry experience, supplemented by board members and investor representatives with deep operating, capital markets, and pharmaceutical expertise. The company is actively expanding geographic reach into China and other emerging markets through partnership-based distribution.

Name

Eywa Pharma

Legal name

Eywa Pharma Pte. Ltd.

Website

https://eywapharma.sg

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Eywa Pharma is a Singapore-headquartered global generic pharmaceutical company developing and commercializing affordable solid oral dosage generics (tablets, capsules, suspensions) across the US, Europe, and Asia through subsidiaries in India, the US, and the UK.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

akta.pro secondary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Oral solid dosage
• Generic drug development
• Pharmaceutical manufacturing
• ANDA filings

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Revenue generated through the sale of generic pharmaceutical products including tablets, capsules, oral suspensions and solutions. Products are sold under the Eywa Label in the US market and under the Zista brand in the UK market through distribution channels including wholesalers, secondary distributors, and buying groups. The company also pursues private label opportunities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Eywa Pharma develops and manufactures generic pharmaceutical products in oral solid dosage forms, including tablets, capsules, oral suspensions, and solutions. The company operates a portfolio of 70+ active products, including niche products with limited or no generic competition, high-volume products, off-patent products, and products addressing historical supply disruptions, marketed under the Eywa Label in the US and under the Zista brand in the UK/Europe. Combination of in-house development at the Chennai facility and in-licensing supports portfolio expansion across multiple therapeutic areas.

Product overview

Eywa Pharma is a global generic pharmaceuticals company that develops and manufactures affordable, high-quality generic medicines. The company operates a portfolio-based business model with products spanning tablets, capsules, oral suspensions and solutions. The core product offering includes niche products with limited generic competition, high-volume products, products expected to go off-patent, and products addressing historical supply disruptions. Products are commercialized under the Eywa Label in the U.S. and under the Zista name in the UK, with strategic private label opportunities including unit dose arrangements. The company maintains development capabilities in Chennai, India and manufacturing capabilities in Cranbury, New Jersey, USA.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceuticals Portfolio Portfolio of generic pharmaceutical products in oral solid dosage forms — tablets, capsules, oral suspensions, and solutions — covering niche products with limited or no generic competition, high-volume products, off-patent products, and products addressing historical supply disruptions across multiple therapeutic areas. Sold under the Eywa Label in the US and the Zista brand in the UK/Europe, with strategic private label opportunities including unit dose products.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Global Development PartnerscoreStrategic or Co-development PartnerStrategic partnerships with development partners globally for generic medicine development. The company has built strategic relationships for development, licensing opportunities, product acquisitions, and marketing partners for niche market segments.
• Licensing PartnerscoreStrategic or Co-development PartnerStrategic in-licensing partners that contribute to Eywa's portfolio build-up. The company uses a combination of in-house development and strategic in-licensing to accelerate portfolio development, including 38+ ANDAs and MAs filed as of December 2019.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Aurobindo Pharma: India-headquartered global generic pharmaceutical company with a large US-focused oral solid dose portfolio and significant ANDA pipeline. Highly comparable to Eywa in business model (India R&D + US commercial) and target markets, but at materially greater scale.
• Dr. Reddy's Laboratories: Indian global generics company with strong US presence, broad oral solid dose portfolio, and active ANDA filing strategy. Shares Eywa's niche + complex generics positioning and India-to-US development-and-commercial model.
• Apotex: Large privately-held Canadian generic pharmaceutical company with a US and Canada commercial footprint and focus on affordable generic medicines. Comparable as a privately-held, multi-jurisdiction generic player pursuing similar limited-competition and difficult-to-make formulations.
• Lannett Company: US-focused generic drug manufacturer specializing in oral solid dose products with a portfolio of niche and limited-competition products. Closely comparable in scale, US-centric commercial model, and niche-generic positioning, including use of third-party manufacturing.
• Glenmark Pharmaceuticals: India-based global pharmaceutical company with a meaningful US generics business built on oral solid dose ANDAs and niche/specialty products. Comparable India-to-US development-and-commercial playbook and product mix.
• Zydus Cadila (Zydus Lifesciences): India-headquartered global generic and specialty pharma company with a strong US ANDA pipeline and broad oral solid dose portfolio. Comparable in geographic reach, dosage form focus, and India-to-US execution model.
• Strides Pharma Science: India-headquartered generic pharmaceutical company with a US-focused oral solid dose business, niche specialty generics, and India R&D plus US commercial operations. Closely matches Eywa's structural model, scale, and product mix.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a vast US ANDA portfolio spanning oral solids and other dosage forms. A broader incumbent whose pricing and capacity decisions shape the competitive dynamics Eywa competes within across all major distribution channels.
• Sandoz (Novartis): Global generic and biosimilar medicines business of Novartis with broad oral solid dose and complex generics portfolio. Sets the competitive baseline in regulated markets where Eywa commercializes and influences wholesaler purchasing decisions.

Others

• Biocon Limited: India-based biopharmaceutical company that acquired Eywa's Cranbury, NJ oral solid dose facility in 2023 and invested over $30M to scale it to 2 billion tablets annual capacity. Adjacent relationship as acquirer of Eywa's manufacturing asset and now an active competitor in US generic OSD supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eywapharma
• Facebookfacebook.com/Eywa-Pharma-987559877929244
• LinkedInlinkedin.com/company/eywa-pharma-pvt.-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eywa Pharma